(firstQuint)Efficacy Study of Single-Dose Levalbuterol Tartrate HFA MDI Vs Placebo in Subjects 18 Years and Older With EIB.

 This was a randomized, double-blind, placebo-controlled, multicenter, two-way crossover study of levalbuterol tartrate HFA MDI in subjects 18 years of age and older with EIB.

 This study was previously posted by Sepracor Inc.

 In October 2009, Sepracor Inc.

 was acquired by Dainippon Sumitomo Pharma.

, and in October 2010, Sepracor Inc's name was changed to Sunovion Pharmaceuticals Inc.

.

 Efficacy Study of Single-Dose Levalbuterol Tartrate HFA MDI Vs Placebo in Subjects 18 Years and Older With EIB@highlight

To determine if administration of levalbuterol tartrate HFA MDI in subjects with EIB will be effective in the prevention of EIB and be safe and well-tolerated.

